Abstract

Endothelial dysfunction or loss is the early event that leads to a host of severe cardiovascular diseases, such as atherosclerosis, hypertension, brain stroke, myocardial infarction, and peripheral artery disease. Ageing is regarded among the most detrimental risk factor for vascular endothelium and predisposes the subject to atheroscleorosis and inflammatory states even in absence of traditional comorbid conditions. Standard treatment to restore blood perfusion through stenotic arteries are surgical or endovascular revascularization. Unfortunately, ageing patients are not the most amenable candidates for such interventions, due to high operative risk or unfavourable vascular involvement. It has recently been suggested that the transplantation of autologous bone marrow-derived endothelial progenitor cells (EPCs) might constitute an alternative and viable therapeutic option for these individuals. Albeit pre-clinical studies demonstrated the feasibility of EPC-based therapy to recapitulate the diseased vasculature of young and healthy animals, clinical studies provided less impressive results in old ischemic human patients. One hurdle associated to this kind of approach is the senescence of autologous EPCs, which are less abundant in peripheral blood and display a reduced pro-angiogenic activity. Conversely, umbilical cord blood (UCB)-derived EPCs are more suitable for cellular therapeutics due to their higher frequency and sensitivity to growth factors, such as vascular endothelial growth factor (VEGF). An increase in intracellular Ca2+ concentration is central to EPC activation by VEGF. We have recently demonstrated that the Ca2+ signalling machinery driving the oscillatory Ca2+ response to this important growth factor is different in UCB-derived EPCs as compared to their peripheral counterparts. In particular, we focussed on the so-called endothelial colony forming cells (ECFCs), which are the only EPC population belonging to the endothelial lineage and able to form capillary-like structures in vitro and stably integrate with host vasculature in vivo. The present review provides a brief description of how exploiting the Ca2+ toolkit of juvenile EPCs to restore the repairative phenotype of senescent EPCs to enhance their regenerative outcome in therapeutic settings.

Highlights

  • Senescence and aging involving several mechanisms like oxidative stress and elevated reactive oxygen species (ROS) (Reactive oxygen species)

  • The injection of autologous endothelial progenitor cells in clinical practice, is still far from coming of age due to the exceedingly number of concerns that have been raised by the lack of therapeutic consistency between pre-clinical studies and clinical trials

  • One of the issues that must be solved before progressing towards a safe application of stem and progenitor cells in the patients is to understand whether and how is possible to rejuvenate the phenotype of senescent endothelial progenitor cells (EPCs), which are inadequate to meet the demands of repair and regeneration in diseased vessels

Read more

Summary

Introduction

Senescence and aging involving several mechanisms like oxidative stress and elevated ROS (Reactive oxygen species). The following reduction in ER Ca2+ levels will activate SOCE This positive feedback between PLCg, DAG, TRPC3, InsP3R and SOCE occurs throughout the oscillatory signal and underpins UCB-proliferation; the rate of cell growth is dramatically impaired upon suppression of VEGF-induced Ca2+ oscillations (manuscript submitted). These findings clearly indicate that juvenile ECFCs may select among a different set of Ca2+ entry/release pathway as compared to their older, i.e. circulating, counterparts. We suggest that TRPC3 is a suitable candidate to reinforce the list of targets that might be exploited to genetically manipulate EPC for CBT purposes

Conclusion
20. Yoder MC
27. Madeddu P
34. Burrig KF
47. Dimmeler S
58. Parekh AB
Findings
Vascularizing the tumor
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.